Actuate Therapeutics Inc (ACTU) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1.72 |
| Open | 1.73 |
| Day High | 1.81 |
| Day Low | 1.65 |
| 52-Week High | 9.22 |
| 52-Week Low | 1.16 |
| Volume | 171,151 |
| Average Volume | 269,369 |
| Market Cap | 39.72M |
| PE | -1.71 |
| EPS | -0.97 |
| Moving Average 50 Days | 2.08 |
| Moving Average 200 Days | 4.33 |
| Change | -0.06 |
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
GlobeNewswire Inc.
Mar 09, 2026 12:45 PM GMT
Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancersMechanisms of action support enhanced activity of GSK-3β plus RAS inhibitionPreclinical combination results expecte
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
GlobeNewswire Inc.
Mar 04, 2026 10:00 PM GMT
CHICAGO and FORT WORTH, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, d
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 24, 2026 1:45 PM GMT
CHICAGO and FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, di